Table 2 Clinical characteristics, immunohistochemical and molecular markers available and response to therapy of patients with grade 3B
N | Total | Mutated EZH2 in FFPE (n = 6) | Unmutated EZH2 in FFPE (n = 7) | p-valor | |
|---|---|---|---|---|---|
(n = 13) | |||||
Clinical characteristics at diagnosis, n (%) | |||||
Age at diagnosis, mean (range) | 13 | 65 (30–85) | 65 (42–84) | 65 (30–85) | 0.775 |
Sex | |||||
Female | 13 | 4 (31) | 3 (50) | 1 (14) | 0.266 |
Male | 9 (69) | 3 (50) | 6 (86) | ||
ECOG | |||||
0–1 | 6 | 6 (100) | 3 (100) | 3 (100) | |
Stage | |||||
I-II | 13 | 3 (23) | 1 (17) | 2 (29) | > 0.999 |
III-IV | 10 (77) | 5 (83) | 5 (71) | ||
FLIPI risk categories | |||||
Low-Intermediate | 9 | 5 (56) | 1 (20) | 4 (100) | 0.048 |
High | 4 (44) | 4 (80) | 0 | ||
Bulky mass | 13 | 4 (31) | 2 (33) | 2 (29) | > 0.999 |
Extranodal | 12 | 1 (8) | 1 (20) | 0 | 0.417 |
Bone narrow infiltration | 13 | 4 (31) | 3 (50) | 1 (14) | 0.266 |
B-symptoms | 13 | 5 (39) | 1 (17) | 4 (57) | 0.266 |
First-line R-CHOP therapy, n (%) | 13 | ||||
Complete remission | 8 (62) | 3 (60) | 5 (71) | 0.54 | |
Progression | 0 | NA | |||
Relapse | 3 (23) | 2 (33) | 1 (14) | 0.2 | |
Not assesseda | 2 (15) | 1 (17) | 1 (14) | ||
Exitus, n (%) | |||||
Yes | 13 | 4 (31) | 1 (17) | 3 (43) | 0.559 |
No | 9 (69) | 5 (83) | 4 (57) | ||